Synchem

Elk Grove Village, United States Founded: 1997 • Age: 29 yrs Acquired By Formosa Laboratories
Custom organic synthesis, medicinal chemistry, and CMC services are provided.

About Synchem

Synchem is a Healthcare company based in Elk Grove Village (United States) founded in 1997 by Daniel Fang and Ze-Qi Xu, and was acquired by Formosa Laboratories in June 2024. Custom organic synthesis, medicinal chemistry, and CMC services are provided. Its chief executive, as recorded, is W Paul Mar. Synchem offers products and services including Process Development, Bioconjugation, Peptide Synthesis, Small Molecule Synthesis, and Catalog Chemicals. Its focus areas include Biopharma Outsourcing, CRO, Drug Discovery and Medicinal Chemistry. Its legal entity is SynChem, Inc.

Company details

Synchem was established in 1997 in Elk Grove Village, United States, as a provider of custom organic synthesis, medicinal chemistry, and CMC services under cGMP conditions. Operations focus on supporting pharmaceutical and biotech clients through project completion, with over 4,500 initiatives delivered. The company is headquartered near Chicago and serves multinational firms in the life sciences sector.

  • Headquarters Elk Grove Village, United States
  • Founders Daniel Fang, Ze-Qi Xu
  • Stage Acquired
  • Sectors
    Healthcare
  • Email
    β€’β€’β€’β€’β€’β€’β€’β€’
  • Phone
    β€’β€’β€’β€’ β€’β€’β€’β€’
  • Website synchem.com
  • Social LinkedIn
  • Acquired by Formosa Laboratories (Jun 2024)
  • Legal Name Synchem, Inc.
Key Metrics

Products & Services of Synchem

Synchem offers a comprehensive portfolio of products and services, including Process Development, Bioconjugation, Peptide Synthesis, Small Molecule Synthesis, and Catalog Chemicals.

Process Development
Service

Provides scalable solutions for chemical efficiency in pharmaceuticals.

Bioconjugation
Service

Enables precision linking for advanced therapeutics development.

Peptide Synthesis
Service

Tailors peptides for therapeutic and innovative applications.

Small Molecule Synthesis
Service

Focuses on precision in complex molecular design and processes.

Catalog Chemicals
Product

Offers ADC-related building blocks for research and development.

Investors in Synchem

Synchem has secured backing from 1 investor. Prominent investors backing the company include Formosa Laboratories.

All
InvestorDescriptionFounded YearDomainLocation
APIs and pharmaceutical intermediates are manufactured by Formosa Laboratories.
1996formosalab.comTaoyuan City, Taiwan
Premium access

Investor details for Synchem

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Board of directors of Synchem

The boards of the 3 registered companies of Synchem currently have 7 directors; the longest-serving is Rajendra Kumar Jain, appointed in 1990. 1 earlier director has ceased.

DirectorDesignationAppointedTenureEntity
Rajendra Kumar Jain
DIN 01895777
Director02 Apr 199036 yrs 6 moSynchem Distributors Pvt Ltd
Jinendra Kumar Jain
DIN 00353133
Whole-time director12 Jul 199630 yrs 3 moSynchem Laboratories Private Limited
Arvindr Kumar Jain
DIN 00353191
Whole-time director12 Jul 199630 yrs 3 moSynchem Laboratories Private Limited
Prdam Kumar Jain
DIN 01014247
Director01 Apr 200026 yrs 6 moSynchem Distributors Pvt Ltd
Dinesh Kumar Jain
DIN 01903486
Whole-time director19 Apr 200026 yrs 6 moSynchem Pharmaceuticals Private Limited
Dharmendra Jain
DIN 00435551
Managing Director19 Apr 200026 yrs 6 moSynchem Pharmaceuticals Private Limited
Manish Jain
DIN 01518865
Whole-time director01 Jun 200719 yrs 4 moSynchem Pharmaceuticals Private Limited

People of Synchem

3 people are tracked at Synchem (3 in leadership).

NameRoleGroup
Daniel Fang
Co-Founder & COOLeadership
Ze-Qi Xu
Co-Founder & CSOLeadership
W Paul Mar
CEOLeadership
Premium access

Complete people profiles for Synchem

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Financials of Synchem

Figures of Synchem Laboratories Private Limited, the primary company behind Synchem, for FY 2024. Revenue was ₹25.30 Cr (+7% year on year). Net profit was ₹3.37 Cr (13% margin). EBITDA was ₹5.23 Cr (21% margin). Revenue has grown at a compounded annual rate of +28% over three years and +15% over five years.

  • ₹25.30 CrRevenue · FY 2024 · +7% YoY
  • ₹3.37 CrNet profit · 13% margin
  • ₹5.23 CrEBITDA · 21% margin
  • ₹7 LakhPaid-up capital
  • +28%Revenue CAGR, 3 years
  • +15%Revenue CAGR, 5 years

Balance sheet, profit and loss, cash flow and ratios of Synchem Laboratories Private Limited are on its company page.

Premium access

Detailed financial statements for Synchem

Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.

  • Statement rows
  • Financial ratios
  • Five-year trends
  • Downloads

Verified entity values are shown only after access is granted.

Timeline of Synchem

2 dated milestones of Synchem across 27 years, from founding to its latest funding, stage changes and deals.

  1. Founded Synchem is founded.
  2. Exit Acquired by Formosa Laboratories.

Web traffic of Synchem

The website of Synchem (synchem.com) receives about 2.6K visits a month.

  • Monthly visits
    2.6K

    ▲ 14% vs previous month

Similar websites

Websites whose visitors overlap most with Synchem. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
amsyn.com
100%
4.1KView details
presschem.com
84%
View details

Top companies in Biopharma Outsourcing & Drug Delivery

3 companies that operate in the same segment as Synchem (Biopharma Outsourcing & Drug Delivery) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Suite solutions are provided for payers and healthcare providers.
1998Princeton, New Jersey, United StatesUSD 220 MUSD 374.1 M4,490
Wearable insulin infusion systems are developed for diabetes patients.
2000Boston, Massachusetts, United StatesUSD 120.4 MUSD 2.71 B3,900
Developer of small-molecule drugs
1991Los Angeles, California, United StatesUSD 50 MUSD 348.97 M407
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Synchem

Premium access

Complete news archive for Synchem

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Synchem

Synchem was founded in 1997.

Synchem is headquartered in Elk Grove Village, United States. It is registered at Elk Grove Village, Illinois, United States.

W Paul Mar is the CEO of Synchem, as recorded in our data.

Synchem was established in 1997 in Elk Grove Village, United States, as a provider of custom organic synthesis, medicinal chemistry, and CMC services under cGMP conditions. Operations focus on supporting pharmaceutical and biotech clients through project completion, with over 4,500 initiatives delivered. The company is headquartered near Chicago and serves multinational firms in the life sciences sector.

Synchem offers Process Development, Bioconjugation, Peptide Synthesis, Small Molecule Synthesis, and Catalog Chemicals.

Synchem has 1 investor. Key investors include Formosa Laboratories.

Synchem is associated with 3 legal entities: Synchem Laboratories Private Limited, Synchem Pharmaceuticals Private Limited, Synchem Distributors Pvt Ltd.

Yes. Synchem was acquired by Formosa Laboratories in June 2024.

The legal entities of Synchem currently have 7 directors, including Jinendra Kumar Jain, Arvindr Kumar Jain, Dinesh Kumar Jain and others.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available